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LETTER TO THE EDITOR
The Role of EBUS-TBNA
for the Assessment of
Hilar Lymph Nodes
To the Editor:
We read with great interest the
article “Efficacy of Endobronchial Ul-
trasound-guided Transbronchial Needle
Aspiration of Hilar Lymph Nodes for
Diagnosing and Staging Cancer” by
Ernst et al.1
Endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-
TBNA) has recently been validated for
the assessment of mediastinal lymph
nodes in patients with (presumed) non-
small cell lung cancer for obtaining ei-
ther a diagnosis or for staging informa-
tion.2 EBUS-TBNA has also been
validated to obtain a diagnosis in pa-
tients with (presumed) centrally located
lung cancer3 or sarcoidosis.4 The current
series now adds a new indication for
EBUS-TBNA.1
An approach to ipsilateral hilar
(N1) nodes can, in certain cases, in-
deed, be the only way to obtain histol-
ogy in patients with a lesion suspect to
be non-small cell lung cancer. In more
rare cases, contralateral (N3) hilar
nodes must be sampled to obtain rele-
vant staging information, as is evident
from this study.
In the implementation of new
medical devices such as EBUS-TBNA,
a precise characterization of the study
population is very relevant information
to select patients for this technique.
Adding data on patient’s characteristics
including T-stage, tumor localization,
fluorodeoxyglucose (18F)-avidity of N1
nodes, and also on the negative predic-
tive value would increase the value of
this study. Another issue the authors did
not comment on is the proportion of
patients with clinical N1 that finally
ended up with pN2. Current guidelines
indeed propose mediastinal staging
(primarily cervical mediastinoscopy)
in case N1 disease is suspected by
imaging.5 Emerging data also show a
high prevalence of unforeseen pN2,6 in-
dicating one could consider mediastinal
staging even before hilar assessment by
EBUS-TBNA. The reason is that the
histologic documentation of cN2 makes
the hilar (N1) assessment redundant.
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